IN THE SPOTLIGHT

A Wealth of Clinical Trials Pushes the Treatment Landscape Forward Across Lung Cancer

A Wealth of Clinical Trials Pushes the Treatment Landscape Forward Across Lung Cancer

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Ensartinib Approved in China for ALK+ NSCLC as 1st Line Treatment

Ensartinib Approved in China for ALK+ NSCLC as 1st Line Treatment

Pfizer: Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

Pfizer: Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC

Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

Study Estimates Impact of Targeted Treatments in NSCLC

Study Estimates Impact of Targeted Treatments in NSCLC

LUNGevity Launches New ALK Patient Gateway'

LUNGevity Launches New ALK Patient Gateway'

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Advanced ALK+ NSCLC: higher levels of cell-free DNA linked to worse outcomes

Advanced ALK+ NSCLC: higher levels of cell-free DNA linked to worse outcomes

Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study

Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study

LUNGevity Launches Campaign Focused on Increasing Lung Cancer Survival by Driving Awareness of Comprehensive Biomarker Testin...

LUNGevity Launches Campaign Focused on Increasing Lung Cancer Survival by Driving Awareness of Comprehensive Biomarker Testin...

LUNGevity Welcomes Amy C. Moore, PhD, as Vice President of Global Engagement and Patient Partnerships

LUNGevity Welcomes Amy C. Moore, PhD, as Vice President of Global Engagement and Patient Partnerships

Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer

Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer

LUNGevity Foundation Amplifies Efforts to Improve Lung Cancer Patient Access to Comprehensive Biomarker Testing through New Awareness Campaign

LUNGevity Foundation Amplifies Efforts to Improve Lung Cancer Patient Access to Comprehensive Biomarker Testing through New Awareness Campaign

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations

FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations

A qualitative study of online support communities for lung cancer survivors on targeted therapies

A qualitative study of online support communities for lung cancer survivors on targeted therapies